Fronza Mariana G, Brod Lucimar M Pinto, Casaril Angela Maria, Sacramento Manoela, Alves Diego, Savegnago Lucielli
Programa de Pós Graduação em Biotecnologia, PPGBiotec, Grupo de Pesquisa em Neurobiotecnologia-GPN, CDTec, Universidade Federal de Pelotas, UFPel, Pelotas, RS, Brazil.
Programa de Pós Graduação em Química, PPGQ, Laboratório de Síntese Orgânica Limpa-LASOL, CCQFA, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
PLoS One. 2017 Nov 1;12(11):e0187445. doi: 10.1371/journal.pone.0187445. eCollection 2017.
A series of phenylselanyl-1H-1,2,3-triazole-4-carbonitriles with different substituents were screened for their binding affinity with serotonin transporter (SERT) and dopamine transporter (DAT) by docking molecular. 5-(4methoxyphenyl)-1-(2-(phenylselanyl)phenyl)-1H-1,2,3-triazole-4-carbonitrile (SeTACN) exhibited the best conformation with SERT even higher than fluoxetine and serotonin, suggesting a competitive inhibition. SeTACN demonstrated additional affinity to other serotonergic receptors involved in antidepressant effects: 5HT1a, 5HT2a and 5HT3. In another set of experiments, SeTACN led to significant reductions in the immobility time of mice submitted to forced swimming test (FST) in the dose range of 0.1- 20mg/kg, suggesting an antidepressant-like effect. The possible mechanism of action was investigated using serotonergic and dopaminergic antagonists. The antidepressant-like effect of SeTACN (0.1mg/kg i.g.) was prevented by the pretreatment with WAY100635 (a selective 5HT1a antagonist), ketanserin (a 5HT2a/c antagonist) and ondansetron (a selective 5ht3 antagonist), PCPA (an inhibitor of serotonin synthesis) but not with SCH23390 (dopaminergic D1 antagonist) and sulpiride (D2 antagonist). Sub-effective dose of fluoxetine was able to potentiate the effects of a sub-effective dose of SeTACN in FST. None of the treatments affected locomotor activity in open field test (OFT). These results together, suggest that the SeTACN antidepressant-like effect is mediate, at least in parts, by serotonergic system.
通过分子对接筛选了一系列具有不同取代基的苯基硒基-1H-1,2,3-三唑-4-甲腈与5-羟色胺转运体（SERT）和多巴胺转运体（DAT）的结合亲和力。5-(4-甲氧基苯基)-1-(2-(苯基硒基)苯基)-1H-1,2,3-三唑-4-甲腈（SeTACN）与SERT呈现出最佳构象，甚至高于氟西汀和5-羟色胺，表明具有竞争性抑制作用。SeTACN对参与抗抑郁作用的其他5-羟色胺能受体：5HT1a、5HT2a和5HT3也表现出额外的亲和力。在另一组实验中，SeTACN在0.1-20mg/kg剂量范围内可显著缩短强迫游泳试验（FST）中小鼠的不动时间，提示具有类抗抑郁作用。使用5-羟色胺能和多巴胺能拮抗剂研究了其可能的作用机制。SeTACN（0.1mg/kg，腹腔注射）的类抗抑郁作用可被WAY100635（一种选择性5HT1a拮抗剂）、酮色林（一种5HT2a/c拮抗剂）、昂丹司琼（一种选择性5ht3拮抗剂）、PCPA（一种5-羟色胺合成抑制剂）预处理所阻断，但不受SCH23390（多巴胺能D1拮抗剂）和舒必利（D2拮抗剂）影响。氟西汀的亚有效剂量能够增强SeTACN亚有效剂量在FST中的作用。所有处理均未影响旷场试验（OFT）中的运动活性。这些结果共同表明，SeTACN的类抗抑郁作用至少部分是由5-羟色胺能系统介导的。
